4-(5-(4-Morpholinophenyl)oxazol-2-ylamino)phenol | 1222343-87-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-(5-(4-Morpholinophenyl)oxazol-2-ylamino)phenol
• 英文别名: 4-[[5-(4-morpholin-4-ylphenyl)-1,3-oxazol-2-yl]amino]phenol
• CAS: 1222343-87-4
• 化学式: C₁₉H₁₉N₃O₃
• 分子量: 337.378
• InChiKey: SWMSZCBNNWCBPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  70.8
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-Azido-1-(4-morpholin-4-ylphenyl)ethanone 、 4-异硫氰酸基-苯酚 在 resin-bound triphenylphosphine 作用下， 以 1,4-二氧六环 为溶剂， 生成 4-(5-(4-Morpholinophenyl)oxazol-2-ylamino)phenol
  参考文献：
  名称：

  2-Anilino-4-aryl-1,3-thiazole inhibitors of valosin-containing protein (VCP or p97)

  摘要：

  Valosin-containing protein (VCP; also known as p97) is a member of the AAA ATPase family with a central role in the ubiquitin-degradation of misfolded proteins. VCP also exhibits antiapoptotic function and metastasis via activation of nuclear factor kappa-B signaling pathway. We have discovered that 2-anilino-4-aryl-1,3-thiazoles are potent drug-like inhibitors of this enzyme. The identified compounds show low nanomolar VCP potency, demonstrate SAR trends, and show activity in a mechanism based cellular assay. This series of compounds represents the first steps towards a novel, small molecule VCP inhibitor as a cancer therapeutic. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.058

文献信息

• 2-Anilino-4-aryl-1,3-thiazole inhibitors of valosin-containing protein (VCP or p97)
  作者：Matthew G. Bursavich、Daniel P. Parker、J. Adam Willardsen、Zhong-Hua Gao、Thaylon Davis、Kirill Ostanin、Rosann Robinson、Ashley Peterson、Daniel M. Cimbora、Ju-Fen Zhu、Burt Richards

  DOI：10.1016/j.bmcl.2010.01.058

  日期：2010.3

  Valosin-containing protein (VCP; also known as p97) is a member of the AAA ATPase family with a central role in the ubiquitin-degradation of misfolded proteins. VCP also exhibits antiapoptotic function and metastasis via activation of nuclear factor kappa-B signaling pathway. We have discovered that 2-anilino-4-aryl-1,3-thiazoles are potent drug-like inhibitors of this enzyme. The identified compounds show low nanomolar VCP potency, demonstrate SAR trends, and show activity in a mechanism based cellular assay. This series of compounds represents the first steps towards a novel, small molecule VCP inhibitor as a cancer therapeutic. (C) 2010 Elsevier Ltd. All rights reserved.